Company Overview

Everest Medicines is a Hong Kong-listed (HKEX 1952.HK) biopharmaceutical company focused on discovering, developing, manufacturing and commercializing transformative pharmaceutical products and vaccines that address critical unmet medical needs for patients in China and other Asian Pacific markets. The management team of Everest Medicines has deep expertise and an extensive track record of high-quality discovery, clinical development, regulatory affairs, CMC, business development, operations and commercialization both in China and with leading global pharmaceutical companies.

Everest Medicines has built a portfolio of potentially global first-in-class or best-in-class molecules in the company’s core therapeutic areas of renal diseases, infectious diseases and autoimmune disorders. Everest Medicines initiated commercial operations in 2021, and is establishing a professional and efficient commercial team across Greater China and other Asia-Pacific markets in anticipation of multiple near-term product approvals. At the same time, the company has set up a strong drug discovery and research team to advance independent research and development, leveraging deep expertise in disease biology, and enabling technologies such as our clinically validated mRNA platform.

To learn more about our approved products and therapeutic candidates in development, click here.